Mediators of Inflammation / 2013 / Article / Fig 3

Research Article

Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 3

Medium- to high-dose C16 therapy reduced CD4+ lymphocytes extravasation (a). C16 late treatment also inhibited CD4+ lymphocytes extravasation to a certain extent (b). Medium to high-dose C16 treatment also reduced CD45+ leukocytes infiltration (c). C16 late treatment also inhibited CD45+ leukocytes infiltration to a certain extent (d). Medium to high-dose C16 treatment reduced CD68+ macrophages extravasation (e). Late treated C16 treatment also inhibited CD68+ macrophages extravasation to a certain extent (f). ((a), (c), (e)) versus normal rats; versus vehicle control rats at week 2 postimmunization group; versus 0.5 mg/per day C16 treated EAE rats at week 2 after immunization. versus vehicle control rats at week 8 after immunization; versus 0.5 mg/per day C16 treated EAE rats at week 8 after immunization. ((b), (d), and (f)) versus normal rats; versus vehicle control rats at week 2 postimmunization group; versus C16 treated EAE rats at week 2 postimmunization group; versus vehicle control rats at week 8 after immunization.
268486.fig.003a
(a)
268486.fig.003b
(b)
268486.fig.003c
(c)
268486.fig.003d
(d)
268486.fig.003e
(e)
268486.fig.003f
(f)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.